Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics Inc (CTMX) is a clinical-stage biopharmaceutical pioneer developing conditionally activated cancer therapies through its probody technology platform. This dedicated news hub provides investors and researchers with essential updates on clinical advancements, strategic collaborations, and therapeutic innovations in oncology.
Access real-time updates on CTMX's probody-based candidates, including antibody drug conjugates and T-cell engagers. The platform centralizes critical developments such as trial milestones, partnership expansions with industry leaders like Astellas and Merck, and financial disclosures - all vital for informed analysis of this innovative oncology company.
Key content categories include clinical program progress, regulatory updates, scientific presentations, and corporate financial results. Each update is curated to highlight how CTMX's tumor-activated therapies aim to improve cancer treatment safety profiles while maintaining therapeutic efficacy.
Bookmark this page for streamlined access to verified CTMX developments. Regularly updated with official press releases and objective reporting, it serves as your primary resource for tracking advancements in conditionally activated cancer immunotherapies.
CytomX Therapeutics reported positive results from the Phase 1 study of CX-2029, the first CD71-targeting antibody-drug conjugate (ADC), highlighting its well-tolerated safety profile.
The study, published in Clinical Cancer Research, involved 45 patients with advanced solid tumors, showing encouraging anti-tumor responses at doses of 2 mg/kg and higher.
The recommended Phase 2 dose is 3 mg/kg every three weeks. The ongoing Phase 2 expansion study targets various cancers, with initial results expected in Q4 2021.
CytomX Therapeutics (Nasdaq: CTMX) is set to participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 2:00 p.m. ET. Dr. Amy Peterson, chief development officer, will represent the company during this event. Investors can access a live webcast on CytomX’s website with an archived replay available for 30 days post-event. CytomX is a leader in oncology-focused therapeutics, utilizing its Probody technology to develop safer, more effective cancer treatments through conditionally activated biologics.
CytomX Therapeutics, Inc. (CTMX) reported its Q1 2021 financial results, highlighting a revenue decrease to $16 million from $49.6 million Y/Y, primarily due to reduced milestone payments. Cash reserves rose to $393.8 million, bolstered by a $108 million public offering. Key advancements include ongoing Phase 2 studies for praluzatamab ravtansine (CX-2009) and CX-2029, targeting unmet cancer needs. The company also faced delays in IND submissions for CX-2043 due to supply chain issues, while expanding collaborations with Bristol Myers Squibb and Amgen.
CytomX Therapeutics (Nasdaq: CTMX) announced it will report its first quarter 2021 financial results on May 6, 2021, after market close. The company will host a conference call at 5:00 p.m. ET to discuss the results and provide a corporate update. CytomX focuses on developing conditionally activated antibody therapeutics for cancer treatment, leveraging its Probody technology. Currently, CytomX has five clinical-stage assets, four in Phase 2 studies, including promising candidates targeting cancer-specific antigens.
CytomX Therapeutics, a clinical-stage biopharmaceutical company, announced the granting of stock options to two new employees. As of April 1, 2021, one employee received options for 120,000 shares at $7.87, and another on April 12, 2021, for 275,000 shares at $6.74. These grants were made under the 2019 Employment Inducement Incentive Plan to attract talent. CytomX focuses on conditionally activated antibody therapeutics targeting cancer, with partnerships with prominent companies such as AbbVie and Bristol Myers Squibb.
CytomX Therapeutics, a clinical-stage oncology biopharmaceutical company, announced a virtual investor event scheduled for April 7, 2021, from 1:00 p.m. to 3:00 p.m. ET. The event will feature industry experts including John Lambert, Sara M. Tolaney, and Melissa L. Johnson, focusing on CytomX’s Probody technology and two investigational ADCs, praluzatamab ravtansine (CX-2009) and CX-2029. A live webcast will be available on CytomX's website, with a replay accessible for 30 days post-event. The company aims to develop safer, more effective cancer therapies.
CytomX Therapeutics (CTMX) reported strong advancements in its clinical pipeline, highlighted by a three-arm Phase 2 study of praluzatamab ravtansine (CX-2009) for breast cancer. The company also continues to enroll patients in the CX-2029 Phase 2 expansion study across four cancer types in collaboration with AbbVie, and Bristol Myers Squibb has expanded its Probody Program into three additional cancer types. In 2020, total revenues reached $100.4 million, up from $57.5 million in 2019, with cash reserves at $316.1 million. The company aims to report initial Phase 2 data in Q4 2021.
CytomX Therapeutics, focused on oncology, announced CEO Sean McCarthy's participation in March virtual healthcare conferences. Key events include the Cowen 41st Annual Virtual Health Care Conference on March 1, 2021, from 1:20-2:20 p.m. ET, and the Barclays Global Virtual Healthcare Conference on March 10, 2021, from 4:45-5:10 p.m. ET. A webcast of the Barclays presentation will be available on CytomX's website, with an archived replay accessible for 90 days. CytomX is pioneering the Probody® technology, developing therapies aimed at more effective cancer treatment.
CytomX Therapeutics (Nasdaq: CTMX) has announced the grant of stock options to a new employee, totaling 65,000 shares at an exercise price of $8.64, aligning with the closing stock price on February 16, 2021. This option issuance is part of the 2019 Employment Inducement Incentive Plan, which aims to attract new talent to the company. CytomX specializes in developing a unique class of antibody therapeutics based on its Probody technology platform, focused on treating cancer more safely and effectively.
CytomX Therapeutics (Nasdaq: CTMX) announced plans to report its fourth quarter and full-year financial results for 2020 on February 24, 2021, after U.S. market close. A conference call will be held at 5:00 p.m. ET to discuss these results and the company's corporate update. CytomX specializes in conditionally-active antibody therapeutics to treat cancer, with a focus on its Probody technology platform. The company is involved in multiple collaborations and has a pipeline featuring several clinical-stage assets, including therapies against difficult-to-drug cancer targets.